Project-005

NIH RePORTER · NIH · UL1 · $436,256 · view on reporter.nih.gov ↗

Abstract

The primary goal of the Hub Research Capacity program is to support innovative research and to provide the requisite tools for investigators to perform safe, high quality translational research. As outlined in the RFA, this component of the CTSA will focus on Integrating Special Populations (ISP) along with Participant and Clinical Interactions (PCI). Our ISP core has extensive resources for performing translational research in various age groups including but not limited to children, older adults, pregnant women and neonates (maternal-fetal medicine), as well as Hispanic populations. Additionally, UTMB has tremendous expertise for investigating rare, orphan diseases such as porphyria, mast cell disease etc. and research on the current US epidemic, opiate use and addictive behaviors (Optional HUB). We are exclusively equipped with a state-of-the-art vaccine development center as a critical arm of preventative care. Our Aim for ISP, will capitalize on existing individual program strengths to collectively broaden our outreach in multicenter trials and underserved communities. The ISP core will be intimately linked with Network Capacity and Informatics. The PCI core will focus its efforts on clinician research education. Specifically, on novel methods to enhance the safety and efficiency for conducting high quality translational research. Moving forward (Aims), clinical trials will be augmented by integrating study coaches, training and support for new clinical studies as well as provide investigators guidance to one of our new satellite studios. Working with Informatics Data Coordinating Center, the PCI core will provide quality control component for new training, monitoring and regulatory aspects for multi-site clinical trials. Additionally, UTMB continues to grow into a larger community area. Towards this end, we will extend UTMB’s Clinical Research Center (CRC) footprint and its human research safety program. To help accomplish these aims, the PCI core will utilize the Office of Clinical Research, the Clinical Research Center (CRC) as well as have strong links with Translational Endeavors and Workforce Development.

Key facts

NIH application ID
10141323
Project number
5UL1TR001439-07
Recipient
UNIVERSITY OF TEXAS MED BR GALVESTON
Principal Investigator
Randall J Urban
Activity code
UL1
Funding institute
NIH
Fiscal year
2021
Award amount
$436,256
Award type
5
Project period
2015-08-18 → 2025-03-31